Clinical trial · no report yet · Phase 3
HER2CLIMB-05
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
- NCT05132582 ↗
- Active not recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- 147 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 83 | |
| Podcasts | 31 | |
| YouTube | 30 | |
| X videos | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- HER2 Positive Breast Cancer
- Interventions
- Tucatinib; Trastuzumab; Pertuzumab; Combination product: Trastuzumab + Pertuzumab; Placebo
- Arms
- Tucatinib + trastuzumab + pertuzumab · Experimental
- Placebo + trastuzumab + pertuzumab · Active comparator
- Enrollment
- 654
- Primary outcomes
- Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Mar 7, 2022
- Primary completion
- Sep 5, 2025
- Results posted
- Yes
- Registry record
- NCT05132582 · updated Sep 29, 2026
Publications
linked from the registry- Dieras V, Curigliano G, Martin M, Lerebours F, Tsurutani J, Savard MF, Jerzak KJ, Hu X, Martins de Aquino Pimentel LC, O'Sullivan CC, Tokunaga E, Okines A, Huang CS, Jacot W, Sohn J, Cronemberger Silva E, Mueller V, Yang S, Granata G, Shen Q, Santarpia L, Hamilton E; HER2CLIMB-05 Investigators. HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer. J Clin Oncol. 2026 Jun 10;44(17):1597-1607. doi: 10.1200/JCO-25-02600. Epub 2025 Dec 10. PubMed 41369677